Back to News
Market Impact: 0.52
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Source: reuters.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Nanexa shares more than doubled in early Friday trading after the Swedish drug-delivery company signed a global licensing agreement with Novo Nordisk worth up to €1.17 billion ($1.33 billion). The deal is a major validation of Nanexa's technology and could materially improve its long-term revenue outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
Ticker Sentiment
NANEXA0.95
NVO0.35
More News
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
- Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
- Stock Movers: UBS, Novo, Hello Fresh (Podcast)
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk
- AI Equity Research Tools for RIAs and Wealth Managers